Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T19:53:43.686Z.
Calculation as of: 2026-10-06T19:53:43.686Z.
Quote observation: 2026-10-06T19:50:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 24a0b8a5defa6360a8df5348432e42fec2fdf5a1d44ff9a0d63a76d612d48360
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$1.10B
EV/FCF Ratio
N/A
TTM Avg
326.12x
3Y Avg
130.24x
5Y Avg
1241.35x
Market Cap
$1.10B
EV/FCF Ratio
N/A
TTM Avg
77.16x
3Y Avg
126.86x
5Y Avg
334.43x
Market Cap
$1.12B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.09B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.08B
EV/FCF Ratio
41.13x
TTM Avg
63.43x
3Y Avg
61.39x
5Y Avg
58.90x
Market Cap
$1.08B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
EV/FCF Ratio
254.08x
TTM Avg
136.50x
3Y Avg
244.79x
5Y Avg
184.87x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Replimune Group, Inc. (REPL) | $1.11B | N/A | N/A | N/A | N/A |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.10B | N/A | 326.12x | 130.24x | 1241.35x |
| STAAR Surgical Company (STAA)vs › | $1.10B | N/A | 77.16x | 126.86x | 334.43x |
| OPKO Health, Inc. (OPK)vs › | $1.09B | N/A | 104.53x | 168.94x | 169.97x |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.12B | N/A | N/A | N/A | N/A |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.09B | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.08B | 41.13x | 63.43x | 61.39x | 58.90x |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.08B | N/A | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 254.08x | 136.50x | 244.79x | 184.87x |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 10.44x | 12.48x | 15.43x | 19.92x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
